NCT03716570View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

April 23, 2021

Study Completion Date

April 23, 2021

Conditions
Parkinson's Disease
Interventions
DRUG

BIIB054

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm.

Trial Locations (9)

791-0295

Research Site, Toon-shi

070-8644

Research Site, Asahikawa-shi

606-8507

Research Site, Kyoto

616-8255

Research Site, Kyoto

980-8574

Research Site, Sendai

982-8555

Research Site, Sendai

565-0871

Research Site, Suita-shi

113-8431

Research Site, Bunkyō City

187-8551

Research Site, Kodaira-shi

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT03716570 - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease | Biotech Hunter | Biotech Hunter